Cell · 2017 · Cell / animal study · PMID 28340339
Explore the library
Preclinical evidenceD-retro-inverso research peptide
FOXO4-DRI
FOXO4-DRI is a laboratory-designed D-retro-inverso peptide studied as a senolytic candidate. Its structure and experimental purpose distinguish it from a naturally occurring FOXO4 protein.
Also indexed as: FOXO4 D-Retro-Inverso peptide
A clear starting point
FOXO4-DRI is a laboratory-designed D-retro-inverso peptide studied as a senolytic candidate. Its structure and experimental purpose distinguish it from a naturally occurring FOXO4 protein.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
FOXO4 / p53 / senescence
FOXO4-DRI is a laboratory-designed D-retro-inverso peptide studied as a senolytic candidate. Its structure and experimental purpose distinguish it from a naturally occurring FOXO4 protein.
- Targets & processes
- FOXO4 / p53 / senescence
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Selective removal of senescent cells in laboratory models.
What this does not establish
The cited research includes cells and mice. Restored tissue markers in mice are not proof of human rejuvenation.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Human toxicology is not established. Manipulating apoptosis and senescence may affect normal repair; selectivity and long-term effects require study.
Contraindications & cautions
Not an exhaustive contraindication review. Human toxicology is not established. Manipulating apoptosis and senescence may affect normal repair; selectivity and long-term effects require study.
Medication & supplement interactions
Interaction information is incomplete. Human toxicology is not established. Manipulating apoptosis and senescence may affect normal repair; selectivity and long-term effects require study.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
This is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.